SILVER SPRING, Md. – An FDA advisory panel Tuesday backed approval of InterMune Inc.'s pirfenidone as a treatment for idiopathic pulmonary fibrosis (IPF), a progressive, irreversible, ultimately fatal disease that affects about 5 million people worldwide, including 100,000 Americans. (BioWorld Today)